0 Replies
WORCESTER, Mass., Apr 28, 2011 (BUSINESS WIRE) — RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that the company’s proposed research collaboration with the University of Massachusetts Medical School (UMMS)... Contine Reading & Discuss→
0 Replies
PASADENA, Calif. - April 27, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced that John J. Rossi, Ph.D., a pioneer and one of the world leaders in the field of RNAi discovery and development, has joined majority... Contine Reading & Discuss→
0 Replies
WORCESTER, Mass., Apr 26, 2011 (BUSINESS WIRE) — RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that it was awarded two Small Business Innovation Research (SBIR) grants from the National... Contine Reading & Discuss→
0 Replies
Stories include:
Gene silencing technology, otherwise known as RNA interference (RNAi), made a big splash when it was discovered a dozen years ago because of its potential to "silence" genes that cause cancers. The approach takes strands of genetic code, programs them to find the gene responsible for a deadly... Contine Reading & Discuss→
0 Replies
Despite the Nobel Prize-winning discovery of RNA interference (RNAi) over a decade ago and the billions of dollars spent developing therapeutic applications, delivery issues continue to challenge the field. To address these problems, researchers are creating novel strategies to achieve a safe and effective mode of delivery.
New approaches were... Contine Reading & Discuss→
0 Replies
WORCESTER, Mass., Apr 15, 2011 (BUSINESS WIRE) — RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using immunotherapy and RNA-targeted technologies, today announced that it has priced an underwritten public offering of 11,950,000 units at a price... Contine Reading & Discuss→
0 Replies
WORCESTER, Mass., Apr 14, 2011 (BUSINESS WIRE) — RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced the completion of its previously announced acquisition of Apthera, Inc. Contine Reading & Discuss→
